Back to search
FDAFDA · Food and drugs·Recall number D-0121-2021

Busulfan Injection 60 mg/10 mL (6 mg/mL), For Intravenous Infusion Only, Must be diluted before use, Single Dose Vial, Sterile, Cytotoxic Agent, Rx Only, 10 mL vial, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, Vial NDC 72485-210-01, Carton NDC 72485-210-08.

Published December 16, 2020 · Recall initiated: December 8, 2020

Summary

FDA records drug Class II recall D-0121-2021, published December 16, 2020 and initiated December 8, 2020. Recalling firm: Shilpa Medicare Limited; Status: Terminated; Reported quantity: 2,064 vials; Lot: Lot #: 7S10008B, Exp. 12/31/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Shilpa Medicare Limited
Distributor
Nationwide in the U.S.
Lot
Lot #: 7S10008B, Exp. 12/31/2020
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Busulfan Injection 60 mg/10 mL (6 mg/mL), For Intravenous Infusion Only, Must be diluted before use, Single Dose Vial, Sterile, Cytotoxic Agent, Rx Only, 10 mL vial, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, Vial NDC 72485-210-01, Carton NDC 72485-210-08. recalled?

Yes. FDA published recall D-0121-2021 on December 16, 2020. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter